课题基金 / 基金详情

SPORE in Prostate Cancer

SPORE in Prostate Cancer
前列腺癌中的孢子
批准号:
9148021
负责人:
HOWARD I SCHER
金额:
$235.0万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-14 至 2021-08-31
关键词:
AddressAndrogen ReceptorAwardBioinformaticsBiological AssayBiological MarkersBiologyBiopsyBloodBlood TestsCastrationClinicalClinical InvestigatorCollaborationsCommunitiesDNA RepairDecision MakingDepartment of DefenseDevelopmentDiseaseDisease ProgressionDisease ResistanceDreamsEarly DiagnosisEvolutionFoundationsFunctional disorderGenomicsGlucocorticoid ReceptorGoalsHeadHeterogeneityHumanIndividualIndolentIndustryInstitutionLeadMalignant NeoplasmsMalignant neoplasm of prostateMedicalMemorial Sloan-Kettering Cancer CenterMolecularMolecular ProfilingMorbidity - disease rateNew AgentsOncologistOutcomePathologistPathway interactionsPatient riskPatient-Focused OutcomesPatientsPharmaceutical PreparationsPre-Clinical ModelProstateProtein IsoformsReceptor SignalingRecommendationReproduction sporesResearchResearch Project GrantsResistanceRiskRoleScienceSystemic TherapyTP53 geneTaxonomyTherapeutic AgentsTherapeutic InterventionTissuesTranslatingTranslational ResearchValidationWorkadvanced diseaseanticancer researchbasecancer clinical trialcancer therapycastration resistant prostate cancercell typeclinical practiceclinically relevantclinically significantcostdesigndrug developmentdrug sensitivityfollow-upimprovedinhibitor/antagonistmenmultidisciplinarynew therapeutic targetnovelnovel diagnosticsnovel therapeuticsprecision medicinepredicting responsepredictive markerpredictive modelingprogramsresistance mechanismtherapy resistanttreatment effecttrial designtumortumor growthtumor heterogeneitytumor progressionworking group

项目摘要

项目成果

HOWARD I SCHER的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 在过去的15年里,纪念斯隆-凯特琳癌症中心的前列腺癌孢子 中心在前列腺癌研究和治疗方面取得了重大进展, 不断发展对肿瘤生长驱动因素的机械理解, 管理整个疾病的临床谱。采用适应风险的方法, 是基于生物标志物的,我们的工作导致了新的诊断血液测试的发展, 预后模型,以区分惰性从临床上显着的癌症,发现新的 治疗靶点,它们在临床前模型中的验证,以及 根据前列腺协会的建议设计的试验中针对他们的药物 癌症工作组。我们的努力影响了全球的临床实践。 最先进的分子分析和生物信息学技术结合, 研究团体承诺获得人类前列腺癌, 所有临床状态的分析,正在迅速导致一个基于生物学的分类,将进一步 完善医疗决策-个性化、精准医疗。在未来5年,我们 该计划将继续关注确定导致疾病的机制 进展和对治疗的耐药性,开发经验证的检测方法,以在患者中识别它们 可以用于临床环境的肿瘤,设计专门的生物标志物试验来验证 他们的临床,并证明其效用,告知医疗决策。我们 我们相信,我们的努力不仅会改善患者的预后,而且会使迫切需要的 新的系统性疗法将更快地成功开发。我们的SPORE是有组织的 5个主要研究项目紧密结合,以实现总体目标。每个 由一名基础和一名临床研究人员领导,他们领导一个多学科团队, 因其出色的翻译潜力和解决危重患者的能力而被选中 需求这种“团队科学”的方法超出了我们计划的范围, 与其他机构和网络、联邦机构和行业的重要合作,包括 其他SPORE和转化科学计划,国防部转型 影响奖,汇集了来自5个前列腺的病理学家和临床肿瘤学家 SPORE用于分析验证基于组织的预测性生物标志物测定, 癌症临床试验联盟,这几乎保证了重要的基础和临床 通过我们的SPORE和我们的研究网络做出和开发的发现是 翻译成快速有效地到达人类终点。
英文摘要
Project Summary Over the past 15 years, the SPORE in Prostate Cancer at Memorial Sloan Kettering Cancer Center has made significant advances in prostate cancer research and treatment, using the evolving mechanistic understanding of the drivers of tumor growth to improve patient management across the clinical spectrum of the disease. Applying a risk-adapted approach that is biomarker based, our work has led to the development of new diagnostic blood tests and prognostic models to distinguish indolent from clinically significant cancers, the discovery of new therapeutic targets, their validation in preclinical models, and the successful development of drugs directed to them in trials designed according to the recommendations of the Prostate Cancer Working Group. Our efforts have impacted clinical practice worldwide. Recent discoveries enabled by state-of-the-art molecular profiling and bioinformatics, combined with a commitment by the research community to obtain human prostate cancers representing all clinical states for analysis, are leading rapidly to a biology-based taxonomy that will further refine medical decision making—personalized, precision medicine. Over the next 5 years, our program will continue to focus on defining the mechanisms that contribute to disease progression and resistance to therapy, developing validated assays to identify them in patient tumors that can be used in a clinical setting, designing dedicated biomarker trials to validate them clinically, and demonstrating their utility to inform medical decision making. We are confident that our efforts will not only improve patient outcomes but will enable urgently needed new systemic therapies to be successfully developed more rapidly. Our SPORE is organized into 5 major research projects that are tightly integrated to achieve the overall objectives. Each is headed by a basic and a clinical investigator who lead a multidisciplinary team that was chosen for its outstanding translational potential and ability to address critical unmet patient needs. This “team science” approach extends beyond the boundaries of our program to include vital collaborations with other institutions and networks, federal agencies, and industry, including other SPOREs and translational science programs, the Department of Defense Transformative Impact Award, which brings together pathologists and clinical oncologists from 5 prostate SPOREs to analytically validate tissue based predictive biomarker assays, and the Prostate Cancer Clinical Trials Consortium, which virtually guarantees that important basic and clinical discoveries made and developed through our SPORE and in our research network are translated to reach human endpoints quickly and efficiently.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers
海外基金